Paraguay Leads Successful Trials of Second Heart Assist Inc.'s Whisper™ Device
Salt Lake City, November 19, 2024 /PRNewswire/ – Utah-based Second Heart Assist Inc. has announced the successful completion of its second set of case studies for the innovative Whisper™ percutaneous mechanical circulatory support device. These trials, conducted in Asunción, Paraguay, were led by Dr. Adrian Ebner, Head of the Cardiovascular Department at the Sanatorio Italiano Hospital, along with his expert team. The study evaluated the safety and effectiveness of the device in six patients suffering from acute decompensated heart failure (ADHF).
Revolutionizing Cardiac Care
The Whisper™ device is designed to enhance cardiac function and renal perfusion, providing crucial support during high-risk percutaneous coronary interventions (HRPCI). Unlike conventional micro-axial pumps that require extremely high rotations per minute (RPMs) to achieve adequate flow, the Whisper™ device operates at lower RPMs. This reduces hemolysis risks, protecting kidney health while delivering efficient cardiovascular support.
Alex Richardson, Chief Technology Officer of Second Heart Assist, commented:
“The Whisper™ device’s ability to generate high flow at low RPMs represents a breakthrough in design, minimizing risks to kidneys and improving overall patient outcomes.”
Dr. Adrian Ebner praised the device, stating:
“The device is incredibly quick and simple to deploy, and its performance at low RPMs is truly remarkable.”
Critical Role in Cardiovascular Care
Percutaneous circulatory assist devices like Whisper™ are essential in high-risk interventions and emergency scenarios, such as acute myocardial ischemia or cardiogenic shock. These devices stabilize cardiac output, improve oxygenation, and prevent organ failure, serving as life-saving tools during critical procedures.
Global Collaboration and Next Steps
Dr. Leslie Miller, Chief Medical Officer of Second Heart Assist, expressed gratitude to the Sanatorio Italiano Hospital team in Paraguay for their exceptional contributions:
“Their diligent efforts have been instrumental in completing this pivotal study, paving the way for expanding our clinical initiatives to the United States.”
The success of these trials underscores Second Heart Assist Inc.’s commitment to advancing cardiac care and highlights the Whisper™ device's potential to transform outcomes for patients with severe cardiac conditions.
About Second Heart Assist Inc.
Second Heart Assist Inc. specializes in developing cutting-edge temporary mechanical circulatory support (MCS) systems. Its flagship product, the Whisper™ device, integrates a stent cage with a motorized impeller to provide essential circulatory support for patients with acute decompensated heart failure (ADHF), cardio-renal syndrome (CRS), or cardiogenic shock (CS). The company also focuses on providing hemodynamic support during high-risk percutaneous coronary interventions.
For more information, visit www.secondheartinc.com.
